|Bid||10.650 x 168100|
|Ask||10.850 x 50000|
|Day's Range||9.845 - 10.060|
|52 Week Range||7.650 - 13.680|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Nicox SA, which obtained U.S. regulatory approval for two products this year, is “no longer at risk of disintegrating,” according to Chief Executive Officer Michele Garufi.
Valeant subsidiary Bausch + Lomb, along with Nicox S.A., received FDA application approval for a new glaucoma drug.
Valeant Pharmaceuticals International Inc. jumped 6.5% in premarket action on Friday after the U.S. Food and Drug Administration late Thursday approved the company's Vyzulta drug. The drug, a treatment ...